Hepatic Steatosis: Causes, Diagnosis, and Evidence-Based Treatment

What Hepatic Steatosis Actually Means

Hepatic steatosis is the medical term for fatty liver. It describes fat deposition in 5% or more of liver cells (hepatocytes), measured by histology or imaging. The term itself is descriptive, not a diagnosis, and the clinical significance depends entirely on the underlying cause and whether inflammation or fibrosis has developed.

Simple Steatosis vs. Steatohepatitis

Simple steatosis (fat without inflammation) carries a relatively benign short-term prognosis. A 2019 meta-analysis of 11 cohort studies (N=411,583) published in Gastroenterology found that simple steatosis increased all-cause mortality risk only modestly compared to the general population [1]. The picture changes when inflammation enters. Steatohepatitis (MASH) involves hepatocyte ballooning, lobular inflammation, and progressive fibrosis risk.

The Lipid Accumulation Process

Triglycerides accumulate in hepatocytes through four mechanisms: increased fatty acid delivery from adipose tissue, increased de novo lipogenesis, decreased fatty acid oxidation, and decreased very-low-density lipoprotein (VLDL) secretion. Insulin resistance drives at least three of these four pathways, which explains why metabolic conditions like type 2 diabetes and obesity so frequently co-occur with hepatic steatosis [2].

MASLD: The New Name for NAFLD

In June 2023, a multi-society Delphi consensus involving over 200 panelists from 56 countries retired the terms NAFLD and NASH. The replacements are MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis) [3].

Why the Terminology Changed

The old terminology had two problems. "Nonalcoholic" defined a disease by what it was not, providing no clinical information about what it was. The term also carried stigma. Patient advocacy groups documented that the "fatty" label discouraged people from seeking care [3].

What the New Criteria Require

MASLD requires hepatic steatosis plus at least one of five cardiometabolic risk factors: BMI ≥25 kg/m² (or ≥23 in Asian populations), fasting glucose ≥100 mg/dL or type 2 diabetes, blood pressure ≥130/85 mmHg, triglycerides ≥150 mg/dL, or HDL cholesterol <40 mg/dL in men / <50 mg/dL in women. Most patients formerly diagnosed with NAFLD meet these criteria. A validation study in Hepatology showed 98.5% concordance between NAFLD and MASLD populations [4].

MetALD: The Overlap Category

The new nomenclature also introduced MetALD for patients who have both metabolic risk factors and moderate alcohol consumption (140-350 g/week for women, 210-420 g/week for men). This replaced the old forced binary between "alcoholic" and "nonalcoholic" liver disease with a spectrum that better reflects clinical reality [3].

How Common Is Hepatic Steatosis?

A 2022 meta-analysis in The Lancet Gastroenterology & Hepatology pooled 72 studies across 17 countries and estimated global NAFLD/MASLD prevalence at 32.4% (95% CI 29.9-34.9), with prevalence rising from 25.5% in studies conducted before 2005 to 37.8% in studies from 2016 onward [5]. That trend has not reversed.

Geographic and Demographic Patterns

Prevalence varies by region: 44.4% in Latin America, 36.5% in the Middle East, 33.8% in South Asia, 30.1% in East Asia, 29.8% in North America, and 25.1% in Western Europe [5]. Men are affected more often than women before menopause, but the gap narrows after age 50. Type 2 diabetes dramatically increases risk. In patients with T2D, prevalence exceeds 55% [6].

The Pediatric Concern

Hepatic steatosis is not limited to adults. A 2015 meta-analysis in Pediatrics found a pooled prevalence of 7.6% in general pediatric populations and 34.2% in obese children [7]. Pediatric MASLD can progress to fibrosis before adulthood.

From Fat to Fibrosis: Disease Progression

Not everyone with hepatic steatosis develops liver damage. The clinical challenge is identifying who will progress.

The Two-Hit and Multiple-Hit Models

The original "two-hit" hypothesis proposed that steatosis (first hit) sensitized the liver to a second insult (oxidative stress, cytokines) that triggered inflammation. Current understanding favors a "multiple parallel hits" model: insulin resistance, adipokine imbalances, endoplasmic reticulum stress, gut microbiome dysbiosis, and genetic susceptibility all act simultaneously [8]. This model explains why progression is variable and unpredictable at the individual level.

Fibrosis Stage Determines Outcomes

Fibrosis stage, not steatosis or inflammation grade, is the strongest predictor of liver-related mortality. A pooled analysis of 1,495 biopsy-confirmed NAFLD patients followed for a median of 12.6 years showed that each one-stage increase in fibrosis (F0 to F4 scale) increased liver-related mortality by 69% (HR 1.69, 95% CI 1.36-2.10) [9]. Patients with F3-F4 fibrosis had a 10-fold increase in liver-related death compared to F0-F1.

Cryptogenic Cirrhosis Connection

Cryptogenic cirrhosis, cirrhosis without an identifiable cause, may represent the end stage of MASH in a substantial number of cases. As MASH progresses to cirrhosis, the hallmark steatosis and inflammation can disappear ("burned-out MASH"), leaving fibrosis without obvious etiology. Studies estimate that 30-75% of cryptogenic cirrhosis cases have metabolic risk factor profiles consistent with prior MASH [10].

Diagnosing Hepatic Steatosis

Diagnosing steatosis is straightforward. Determining whether fibrosis is present requires more effort.

Imaging Methods

Conventional ultrasound detects steatosis when fat content exceeds roughly 20-30% of hepatocytes, making it insensitive to mild disease. Controlled attenuation parameter (CAP), measured by transient elastography (FibroScan), quantifies steatosis with better precision (AUROC 0.82-0.87 for detecting ≥5% steatosis) [11]. MRI-derived proton density fat fraction (MRI-PDFF) is the most accurate noninvasive tool, detecting as little as 3-5% hepatic fat content, and serves as the primary endpoint in most clinical trials [11].

Noninvasive Fibrosis Assessment

The FIB-4 index uses four readily available values (age, AST, ALT, platelet count) to estimate fibrosis risk. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance recommends FIB-4 as the first-line screening tool [12]. A FIB-4 score <1.3 has a negative predictive value exceeding 90% for advanced fibrosis. Scores ≥1.3 warrant second-line testing with vibration-controlled transient elastography (VCTE) or the Enhanced Liver Fibrosis (ELF) test.

When Biopsy Is Still Needed

Liver biopsy remains the reference standard for grading steatohepatitis and staging fibrosis. The AASLD guidance recommends biopsy when noninvasive tests are indeterminate, when competing etiologies need exclusion, or before initiating pharmacotherapy for MASH [12]. Biopsy carries a small but real complication risk (pain in 20-30%, significant bleeding in 0.1-0.5%).

Lifestyle Interventions: The Foundation

Weight loss is the most effective intervention for hepatic steatosis. The dose-response relationship is well established.

Weight Loss Thresholds

A prospective Cuban study of 293 patients with biopsy-confirmed NASH showed that 3-5% weight loss resolved steatosis in 35-60% of patients, 7-10% loss resolved steatohepatitis in up to 65%, and greater than 10% loss improved fibrosis in 45% [13]. The AASLD and European Association for the Study of the Liver (EASL) both recommend a minimum 7-10% weight loss target for patients with MASH [12].

Exercise Independent of Weight Loss

Physical activity reduces hepatic fat even without significant weight change. A meta-analysis of 12 randomized trials (N=648) in Hepatology found that exercise reduced intrahepatic lipid content by 3.31 percentage points (95% CI -4.41 to -2.22) compared to controls, regardless of body weight change [14]. Both aerobic and resistance training showed benefit. Current guidance recommends 150-300 minutes per week of moderate-intensity aerobic activity.

Dietary Patterns

The Mediterranean diet has the strongest evidence base for MASLD. A 2022 randomized trial (N=294) comparing Mediterranean diet to low-fat diet over 18 months showed greater reductions in intrahepatic fat content with the Mediterranean approach, particularly when enriched with polyphenol-rich foods and Mankai duckweed [15]. Fructose-sweetened beverages and ultra-processed foods are specifically linked to hepatic de novo lipogenesis and should be minimized.

Pharmacotherapy for MASH

Drug treatment targets patients with biopsy-confirmed MASH, particularly those with significant fibrosis (F2 or higher).

Resmetirom (Rezdiffra): The First Approved Drug

The FDA approved resmetirom in March 2024 for MASH with moderate-to-advanced liver fibrosis (F2-F3), making it the first drug approved specifically for this indication. The MAESTRO-NASH trial (N=966) showed that resmetirom 100 mg daily achieved MASH resolution without worsening fibrosis in 29.9% of patients vs. 9.7% with placebo at 52 weeks (P<0.001). The 80 mg dose achieved MASH resolution in 25.9% vs. 9.7% placebo [16]. Both doses also significantly reduced LDL cholesterol, a finding relevant given that cardiovascular disease kills more MASLD patients than liver disease.

GLP-1 Receptor Agonists

Semaglutide showed significant promise in the phase 2 trial by Newsome et al., published in the New England Journal of Medicine. At 72 weeks, semaglutide 0.4 mg daily achieved NASH resolution in 59% of patients vs. 17% with placebo (P<0.001). Fibrosis improvement did not reach statistical significance in this trial, though a numerical trend favored semaglutide [17]. The phase 3 ESSENCE trial subsequently demonstrated both MASH resolution and fibrosis improvement with semaglutide 2.4 mg weekly.

Pioglitazone

Pioglitazone, a thiazolidinedione, has consistent evidence for MASH resolution, particularly in patients with type 2 diabetes. The PIVENS trial (N=247) showed that pioglitazone 30 mg daily achieved NASH resolution in 47% of non-diabetic patients vs. 21% with placebo at 96 weeks [18]. Weight gain (mean 4.7 kg) and bone density loss limit its long-term use, especially in postmenopausal women.

Vitamin E

In the same PIVENS trial, vitamin E 800 IU daily achieved NASH resolution in 36% vs. 21% placebo (P=0.005) [18]. The AASLD suggests vitamin E as a treatment option for non-diabetic adults with biopsy-confirmed NASH, though long-term safety concerns (a contested association with increased prostate cancer risk from the SELECT trial) have tempered enthusiasm.

Managing Comorbidities in MASLD

Cardiovascular disease, not liver failure, is the primary killer. Treatment must address the full metabolic profile.

Cardiovascular Risk Reduction

A meta-analysis of 34 studies (N=164,494) found that NAFLD increased the risk of cardiovascular events by 45% (HR 1.45, 95% CI 1.31-1.61) and cardiovascular mortality by 29% [19]. Statin therapy is safe in MASLD and compensated cirrhosis. The Dallas Heart Study and multiple retrospective analyses confirm that statins do not worsen liver disease and may reduce hepatic fibrosis. Avoiding statins because of mildly elevated transaminases is a common clinical error.

Type 2 Diabetes and MASLD

The relationship is bidirectional. MASLD promotes insulin resistance, and insulin resistance accelerates hepatic fat accumulation. For patients with both conditions, GLP-1 receptor agonists and pioglitazone address both diseases simultaneously. SGLT2 inhibitors (empagliflozin, dapagliflozin) have shown reductions in hepatic fat content in smaller studies, though large MASH-specific trials are ongoing [20].

Obstructive Sleep Apnea

Intermittent hypoxia from untreated obstructive sleep apnea (OSA) independently promotes hepatic steatosis and fibrosis through HIF-1α activation. Cross-sectional studies report OSA prevalence of 50-80% in patients with MASLD. Screening for OSA should be part of the MASLD workup, particularly in patients with BMI ≥30 or excessive daytime sleepiness.

Progression to Cirrhosis and Hepatocellular Carcinoma

MASH is now the fastest-growing indication for liver transplantation in the United States.

Cirrhosis Trajectory

Paired-biopsy studies show that 21-25% of patients with MASH develop bridging fibrosis or cirrhosis over 10-15 years [9]. Once cirrhosis establishes, decompensation (ascites, variceal bleeding, hepatic encephalopathy) occurs at a rate of approximately 3-4% per year.

Hepatocellular Carcinoma Risk

MASH-related HCC can develop even without cirrhosis, a pattern less common in viral hepatitis. An estimated 20-50% of MASLD-associated HCC occurs in non-cirrhotic livers, complicating surveillance strategies [21]. Current AASLD guidance recommends HCC surveillance with ultrasound (with or without alpha-fetoprotein) every six months for patients with MASH cirrhosis, but no formal recommendation exists for non-cirrhotic MASLD patients.

Liver Transplantation Considerations

MASH cirrhosis accounted for approximately 20% of liver transplant listings in the U.S. By 2023, up from under 2% in 2002. Post-transplant outcomes are comparable to other etiologies, though metabolic comorbidities (obesity, diabetes, cardiovascular disease) increase perioperative risk [22]. Recurrent MASLD in the graft occurs in 60-100% of recipients, and recurrent MASH in 10-33%.

Emerging Therapies and Pipeline

Multiple phase 3 programs are underway for MASH treatment beyond resmetirom.

FGF21 Analogues

Efruxifermin, a long-acting FGF21 analogue, showed a 39% rate of fibrosis improvement by at least one stage (vs. 20% placebo) in the phase 2b HARMONY trial at 24 weeks. The SYNCHRONY Outcomes trial (phase 3) is actively enrolling. Pegozafermin, another FGF21 analogue, demonstrated similar activity in the phase 2b ENLIVEN trial with 27% fibrosis improvement vs. 7% placebo at 24 weeks [23].

Thyroid Hormone Receptor Beta Agonists

Resmetirom is the first in class, but other THR-β agonists are in development. The mechanism (selective activation of the thyroid hormone receptor beta in hepatocytes) promotes fatty acid oxidation and reduces de novo lipogenesis without the cardiac effects of systemic thyroid hormone activation.

Combination Approaches

Given the multiple parallel pathways driving MASH, single-agent therapies may prove insufficient for patients with advanced disease. Trials combining GLP-1 receptor agonists with THR-β agonists or FGF21 analogues are in planning or early-phase stages. The treatment approach for MASH is likely to mirror cardiology and oncology, where combination regimens outperform monotherapy for complex disease.

When to Refer to Hepatology

Primary care clinicians manage most patients with hepatic steatosis. Referral criteria include FIB-4 ≥2.67 (high probability of advanced fibrosis), liver stiffness ≥12 kPa on VCTE, persistently unexplained transaminase elevation after 6 months, suspected cirrhosis (thrombocytopenia, splenomegaly, stigmata of chronic liver disease), or candidacy for MASH-specific pharmacotherapy. The AASLD 2023 practice guidance provides a detailed referral algorithm starting with FIB-4 in any patient with hepatic steatosis and metabolic risk factors [12].